DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2018, it provided dialysis and administrative services in the United States through a network of 2,664 outpatient dialysis centers serving approximately 202,700 patients; and operated 241 outpatient dialysis centers located in 9 countries outside of the United States serving approximately 25,000 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Services
SectorMedical
Phone720-631-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.40 billion
Profitability
Miscellaneous
Employees74,500
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Davita (NYSE:DVA) Frequently Asked Questions
What is Davita's stock symbol?
Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."
How will Davita's stock buyback program work?
Davita declared that its board has authorized a stock buyback program on Wednesday, October 11th 2017, which allows the company to repurchase $1,500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its shares are undervalued.
How were Davita's earnings last quarter?
Davita Inc (NYSE:DVA) issued its quarterly earnings results on Wednesday, February, 13th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.89 by $0.01. The firm earned $2.82 billion during the quarter, compared to the consensus estimate of $2.97 billion. Davita had a net margin of 1.40% and a return on equity of 14.17%. The business's revenue was up 1.4% compared to the same quarter last year. During the same period last year, the business posted $0.92 EPS. View Davita's Earnings History.
When is Davita's next earnings date?
What price target have analysts set for DVA?
9 Wall Street analysts have issued 1-year price targets for Davita's stock. Their forecasts range from $59.00 to $70.00. On average, they anticipate Davita's stock price to reach $64.5733 in the next twelve months. This suggests a possible upside of 21.9% from the stock's current price. View Analyst Price Targets for Davita.
What is the consensus analysts' recommendation for Davita?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Davita.
Has Davita been receiving favorable news coverage?
News coverage about DVA stock has trended somewhat positive recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Davita earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Davita's key competitors?
Some companies that are related to Davita include Takeda Pharmaceutical (TAK), Takeda Pharmaceutical (TKPYY), FRESENIUS SE &/S (FSNUY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), ESSILOR INTL S/S (ESLOY), Zimmer Biomet (ZBH), Centene (CNC), Eisai (ESALY), Fresenius Medical Care AG & Co. (FMS), TERUMO CORP/ADR (TRUMY), McKesson (MCK), LONZA GRP AG/ADR (LZAGY), Fresenius Medical Care AG & Co. KGaA (FME) and COLOPLAST A/S/ADR (CLPBY).
What other stocks do shareholders of Davita own?
Who are Davita's key executives?
Davita's management team includes the folowing people:
- Mr. Kent J. Thiry, Chairman & CEO (Age 63)
- Mr. Joel Ackerman, Chief Financial Officer (Age 54)
- Mr. James K. Hilger, Chief Accounting Officer (Age 57)
- Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 51)
- Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 48)
Who are Davita's major shareholders?
Davita's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.79%), Norges Bank (3.22%), Dimensional Fund Advisors LP (1.55%), Gates Capital Management Inc. (1.34%), FMR LLC (1.22%) and Oregon Public Employees Retirement Fund (1.13%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita.
Which institutional investors are selling Davita stock?
DVA stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Millennium Management LLC, Partner Fund Management L.P., Consulta Ltd, Bank of New York Mellon Corp, Manning & Napier Group LLC, Two Sigma Investments LP and KBC Group NV. Company insiders that have sold Davita company stock in the last year include Charles Berg, Pamela M Arway and William L Roper. View Insider Buying and Selling for Davita.
Which institutional investors are buying Davita stock?
DVA stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, BlackRock Inc., Oregon Public Employees Retirement Fund, DPM Capital LLC, Caption Management LLC, Gates Capital Management Inc., Toronto Dominion Bank and First Trust Advisors LP. View Insider Buying and Selling for Davita.
How do I buy shares of Davita?
Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Davita's stock price today?
One share of DVA stock can currently be purchased for approximately $52.96.
How big of a company is Davita?
Davita has a market capitalization of $8.81 billion and generates $11.40 billion in revenue each year. The company earns $159.39 million in net income (profit) each year or $3.57 on an earnings per share basis. Davita employs 74,500 workers across the globe.
What is Davita's official website?
How can I contact Davita?
Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 720-631-2100 or via email at [email protected]
MarketBeat Community Rating for Davita (NYSE DVA)
MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
